Sonia Sequeira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sonia Sequeira has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Barney Yoo
Department of Chemistry, Hunter College, City University of New York, NY 10065, USA
2 shared publications Mahiuddin Ahmed
Department of Pediatrics †Office of Clinical Research, Memorial Sloan-Kettering Cancer Center, New York, NY
2 shared publications- Michelle S. Bradbury
Department of Radiology, Weill Cornell Medicine, New York, USA
2 shared publications - Ulrich Wiesner
Cornell University
2 shared publications Afsar Barlas
Molecular Cytology Core Facility, Memorial Sloan-Kettering Cancer Center, New York, USA
1 shared publicationAlexander Bolaender
Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication
Latest Publications
- Open Access
- 16 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-19
The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction
Optimal functioning of neuronal networks is critical to the complex cognitive processes of memory and executive function that deteriorate in Alzheimer’s disease (AD). Here we use cellular and animal models as well as human biospecimens to show that AD-related stressors mediate global disturbances in dynamic intra- and inter-neuronal networks through pathologic rewiring of the chaperome system into epichaperomes. These structures provide the backbone upon which proteome-wide connectivity, and in turn, protein networks become disturbed and ultimately dysfunctional. We introduce the term protein connectivity-based dysfunction (PCBD) to define this mechanism. Among most sensitive to PCBD are pathways with key roles in synaptic plasticity. We show at cellular and target organ levels that network connectivity and functional imbalances revert to normal levels upon epichaperome inhibition. In conclusion, we provide proof-of-principle to propose AD is a PCBDopathy, a disease of proteome-wide connectivity defects mediated by maladaptive epichaperomes.
- 16 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-19
Open AccessThe epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction
Optimal functioning of neuronal networks is critical to the complex cognitive processes of memory and executive function that deteriorate in Alzheimer’s disease (AD). Here we use cellular and animal models as well as human biospecimens to show that AD-related stressors mediate global disturbances in dynamic intra- and inter-neuronal networks through pathologic rewiring of the chaperome system into epichaperomes. These structures provide the backbone upon which proteome-wide connectivity, and in turn, protein networks become disturbed and ultimately dysfunctional. We introduce the term protein connectivity-based dysfunction (PCBD) to define this mechanism. Among most sensitive to PCBD are pathways with key roles in synaptic plasticity. We show at cellular and target organ levels that network connectivity and functional imbalances revert to normal levels upon epichaperome inhibition. In conclusion, we provide proof-of-principle to propose AD is a PCBDopathy, a disease of proteome-wide connectivity defects mediated by maladaptive epichaperomes.
- Open Access
- 6 December 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (12) , eaax5208
Molecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles
Spectrally distinct ultrasmall fluorescence silica particles as multiplexing tools address cancer heterogeneity and aid surgery.
- 6 December 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (12) , eaax5208
Open AccessMolecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles
Spectrally distinct ultrasmall fluorescence silica particles as multiplexing tools address cancer heterogeneity and aid surgery.
- 1 November 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (22) , 7119-7130
Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization
- 1 November 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (22) , 7119-7130
Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization
- 1 March 2014
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 36 (2) , 152-155
Acute Pain Relief After Mantram Meditation in Children With Neuroblastoma Undergoing Anti-GD2 Monoclonal Antibody Therapy
Nonpharmacologic, mind-body interventions are used to reduce anxiety in pediatric patients. Anti-ganglioside GD2 monoclonal antibody (anti-GD2 MoAb 3F8) therapy is the standard of care for high-risk neuroblastoma and pain is its major side effect. We performed a retrospective analysis of children undergoing anti-GD2 MoAb 3F8 treatment who received guided meditation. Meditation involved concentrating on the repetition of rhythmic, melodic sounds purported to slow breathing and induce a relaxation response. A total of 71% patients completed a session at first (n=19) or second attempt (n=5). Patients received fewer analgesic doses to manage anti-GD2 MoAb 3F8-induced pain when participating in meditation (n=17, mean=-0.4 dose, P<0.01). Mantram meditation is a feasible outpatient intervention associated with reduced analgesic requirements.
- 1 March 2014
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 36 (2) , 152-155
Acute Pain Relief After Mantram Meditation in Children With Neuroblastoma Undergoing Anti-GD2 Monoclonal Antibody Therapy
Nonpharmacologic, mind-body interventions are used to reduce anxiety in pediatric patients. Anti-ganglioside GD2 monoclonal antibody (anti-GD2 MoAb 3F8) therapy is the standard of care for high-risk neuroblastoma and pain is its major side effect. We performed a retrospective analysis of children undergoing anti-GD2 MoAb 3F8 treatment who received guided meditation. Meditation involved concentrating on the repetition of rhythmic, melodic sounds purported to slow breathing and induce a relaxation response. A total of 71% patients completed a session at first (n=19) or second attempt (n=5). Patients received fewer analgesic doses to manage anti-GD2 MoAb 3F8-induced pain when participating in meditation (n=17, mean=-0.4 dose, P<0.01). Mantram meditation is a feasible outpatient intervention associated with reduced analgesic requirements.
- 13 January 2014
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1307 (1)
Foreword to Advances in Meditation Research: Neuroscience and Clinical Applications
- 13 January 2014
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1307 (1)
Foreword to Advances in Meditation Research: Neuroscience and Clinical Applications
- Open Access
- 4 June 2012
- Published by Hindawi Limited in Autism Research and Treatment
- Vol. 2012, 1-11
Meditation as a Potential Therapy for Autism: A Review
Autism is a chronic neurodevelopmental disorder of unknown cause that affects approximately 1–3 percent of children and four times more boys than girls. Its prevalence is global and its social impact is devastating. In autism, the brain is unable to process sensory information normally. Instead, simple stimuli from the outside world are experienced as overwhelmingly intense and strain the emotional centers of the brain. A stress response to the incoming information is initiated that destabilizes cognitive networks and short-circuits adequate behavioral output. As a result, the child is unable to respond adequately to stimulation and initiate social behavior towards family, friends, and peers. In addition, these children typically face immune-digestive disorders that heighten social fears, anxieties, and internal conflicts. While it is critical to treat the physical symptoms, it is equally vital to offer an evidence-based holistic solution that harmonizes both their emotional and physical well-being as they move from childhood into adult life. Here, we summarize evidence from clinical studies and neuroscience research that suggests that an approach built on yogic principles and meditative tools is worth pursuing. Desired outcomes include relief of clinical symptoms of the disease, greater relaxation, and facilitated expression of feelings and skills, as well as improved family and social quality of life.
- 4 June 2012
- Published by Hindawi Limited in Autism Research and Treatment
- Vol. 2012, 1-11
Open AccessMeditation as a Potential Therapy for Autism: A Review
Autism is a chronic neurodevelopmental disorder of unknown cause that affects approximately 1–3 percent of children and four times more boys than girls. Its prevalence is global and its social impact is devastating. In autism, the brain is unable to process sensory information normally. Instead, simple stimuli from the outside world are experienced as overwhelmingly intense and strain the emotional centers of the brain. A stress response to the incoming information is initiated that destabilizes cognitive networks and short-circuits adequate behavioral output. As a result, the child is unable to respond adequately to stimulation and initiate social behavior towards family, friends, and peers. In addition, these children typically face immune-digestive disorders that heighten social fears, anxieties, and internal conflicts. While it is critical to treat the physical symptoms, it is equally vital to offer an evidence-based holistic solution that harmonizes both their emotional and physical well-being as they move from childhood into adult life. Here, we summarize evidence from clinical studies and neuroscience research that suggests that an approach built on yogic principles and meditative tools is worth pursuing. Desired outcomes include relief of clinical symptoms of the disease, greater relaxation, and facilitated expression of feelings and skills, as well as improved family and social quality of life.
- 1 October 2004
- Published by Wiley in Protein Science
- Vol. 13 (10) , 2665-2672
Crystallographic identification of Ca2+ and Sr2+ coordination sites in synaptotagmin I C2B domain
Synaptotagmin I has two tandem Ca2+‐binding C2 domains, which are essential for fast synchronous synaptic transmission in the central nervous system. We have solved four crystal structures of the C2B domain, one of them in the cation‐free form at 1.50 Å resolution, two in the Ca2+‐bound form at 1.04 Å (two bound Ca2+ ions) and 1.65 Å (three bound Ca2+ ions) resolution and one in the Sr2+‐bound form at 1.18 Å (one bound Sr2+ ion) resolution. The side chains of four highly conserved aspartic acids (D303, D309, D363, and D365) and two main chain oxygens (M302:O and Y364:O), together with water molecules, are in direct contact with two bound Ca2+ ions (sites 1 and 2). At higher Ca2+ concentrations, the side chain of N333 rotates and cooperates with D309 to generate a third Ca2+ coordination site (site 3). Divalent cation binding sites 1 and 2 in the C2B domain were previously identified from NMR NOE patterns and titration studies, supplemented by site‐directed mutation analysis. One difference between the crystal and NMR studies involves D371, which is not involved in coordination with any of the identified Ca2+ sites in the crystal structures, while it is coordinated to Ca2+ in site 2 in the NMR structure. In the presence of Sr2+, which is also capable of triggering exocytosis, but with lower efficiency, only one cation binding site (site 1) was occupied in the crystallographic structure.
- 1 October 2004
- Published by Wiley in Protein Science
- Vol. 13 (10) , 2665-2672
Crystallographic identification of Ca2+ and Sr2+ coordination sites in synaptotagmin I C2B domain
Synaptotagmin I has two tandem Ca2+‐binding C2 domains, which are essential for fast synchronous synaptic transmission in the central nervous system. We have solved four crystal structures of the C2B domain, one of them in the cation‐free form at 1.50 Å resolution, two in the Ca2+‐bound form at 1.04 Å (two bound Ca2+ ions) and 1.65 Å (three bound Ca2+ ions) resolution and one in the Sr2+‐bound form at 1.18 Å (one bound Sr2+ ion) resolution. The side chains of four highly conserved aspartic acids (D303, D309, D363, and D365) and two main chain oxygens (M302:O and Y364:O), together with water molecules, are in direct contact with two bound Ca2+ ions (sites 1 and 2). At higher Ca2+ concentrations, the side chain of N333 rotates and cooperates with D309 to generate a third Ca2+ coordination site (site 3). Divalent cation binding sites 1 and 2 in the C2B domain were previously identified from NMR NOE patterns and titration studies, supplemented by site‐directed mutation analysis. One difference between the crystal and NMR studies involves D371, which is not involved in coordination with any of the identified Ca2+ sites in the crystal structures, while it is coordinated to Ca2+ in site 2 in the NMR structure. In the presence of Sr2+, which is also capable of triggering exocytosis, but with lower efficiency, only one cation binding site (site 1) was occupied in the crystallographic structure.
- Open Access
- 15 July 2002
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 158 (2) , 273-282
Calcium-independent stimulation of membrane fusion and SNAREpin formation by synaptotagmin I
Ñeurotransmitter release requires the direct coupling of the calcium sensor with the machinery for membrane fusion. SNARE proteins comprise the minimal fusion machinery, and synaptotagmin I, a synaptic vesicle protein, is the primary candidate for the main neuronal calcium sensor. To test the effect of synaptotagmin I on membrane fusion, we incorporated it into a SNARE-mediated liposome fusion assay. Synaptotagmin I dramatically stimulated membrane fusion by facilitating SNAREpin zippering. This stimulatory effect was topologically restricted to v-SNARE vesicles (containing VAMP 2) and only occurred in trans to t-SNARE vesicles (containing syntaxin 1A and SNAP-25). Interestingly, calcium did not affect the overall fusion reaction. These results indicate that synaptotagmin I can directly accelerate SNARE-mediated membrane fusion and raise the possibility that additional components might be required to ensure tight calcium coupling.
- 15 July 2002
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 158 (2) , 273-282
Open AccessCalcium-independent stimulation of membrane fusion and SNAREpin formation by synaptotagmin I
Ñeurotransmitter release requires the direct coupling of the calcium sensor with the machinery for membrane fusion. SNARE proteins comprise the minimal fusion machinery, and synaptotagmin I, a synaptic vesicle protein, is the primary candidate for the main neuronal calcium sensor. To test the effect of synaptotagmin I on membrane fusion, we incorporated it into a SNARE-mediated liposome fusion assay. Synaptotagmin I dramatically stimulated membrane fusion by facilitating SNAREpin zippering. This stimulatory effect was topologically restricted to v-SNARE vesicles (containing VAMP 2) and only occurred in trans to t-SNARE vesicles (containing syntaxin 1A and SNAP-25). Interestingly, calcium did not affect the overall fusion reaction. These results indicate that synaptotagmin I can directly accelerate SNARE-mediated membrane fusion and raise the possibility that additional components might be required to ensure tight calcium coupling.